CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Incidence rate and risk factors of second primary neoplasms among older patients with hematological malignancies: Insights from a Chinese single-center experience (1997-2021).
Incidence rate and risk factors of second primary neoplasms among older patients with hematological malignancies: Insights from a Chinese single-center experience (1997-2021).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这些发现强调了向老年血液系统恶性肿瘤患者告知第二原发肿瘤长期风险的重要性。
血液系统恶性肿瘤患者由于免疫系统受损和化疗相关影响等多种因素,发生第二原发肿瘤的风险升高。然而,老年患者中第二原发肿瘤的发生率及相关危险因素仍缺乏充分了解。本研究旨在评估老年血液系统恶性肿瘤患者第二原发肿瘤的发生率、识别危险因素,并评估其对生存结局的影响。
这项单中心回顾性研究分析了 163 例患者的数据,重点考察第二原发肿瘤的发生。计算累积发生率,并采用竞争风险模型分析危险因素。
在符合条件的 124 例患者中,总随访时间为 572.57 人年,第二原发肿瘤发生率为每 1,000 人年 15.72 例。标准化发病比(SIR)为 0.81(95% 置信区间 [0.39–1.48],P = 0.518)。既往放疗是显著危险因素(亚分布风险比 [SHR] = 21.61 [2.81–166.14],P = 0.003);定期输注自然杀伤(NK)细胞则与风险降低相关(SHR = 3.25 × 10⁻⁸ [9.81 × 10⁻⁹–1.08 × 10⁻⁷],P < 0.001)。
这些发现凸显了向老年血液系统恶性肿瘤患者说明第二原发肿瘤长期风险的重要性。医务人员制定治疗策略时应审慎权衡危险因素。研究结果有助于探讨第二原发肿瘤发生和进展的基本规律。
Patients with hematological malignancies face an increased risk of developing second primary neoplasms due to various factors, including immune system compromise and chemotherapy-related effects. However, the incidence and associated risk factors in older patients remain poorly understood. This study aimed to assess the incidence, identify risk factors, and evaluate their impact on survival outcomes among older patients with hematological malignancies.
This retrospective single-center study analyzed data from 163 patients, focusing on the occurrence of second primary neoplasms. Cumulative incidence rates were calculated, and risk factor analysis was conducted using a competing risk model.
Among 124 eligible patients with a total follow-up duration of 572.57 person-years, the incidence rate of second primary neoplasms was 15.72/1000 person-years. The standardized incidence ratio (SIR) was 0.81 (95% confidence interval [CI] [0.39-1.48], P = 0.518). History of radiotherapy emerged as a significant risk factor (sub-distribution hazard ratio [SHR] = 21.61 [2.81-166.14], P = 0.003), whereas regular natural killer (NK) cell infusion was associated with reduced risk (SHR = 3.25 e-8 [9.81 e-9-1.08 e-7], P 0.001).
These findings underscore the importance of informing older patients with hematological malignancies about the long-term risks of second primary neoplasms. Healthcare providers should carefully weigh risk factors when formulating treatment strategies. The results are valuable for investigating the fundamental principles underlying the occurrence and progression of second primary neoplasms.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。